{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:53:30Z","timestamp":1791687210393,"version":"4.3.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jval.2023.02.007","type":"journal-article","created":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T02:20:49Z","timestamp":1676686849000},"page":"1155-1163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping"],"prefix":"10.1016","volume":"26","author":[{"given":"Mo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Vioix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma S.","family":"Hook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Hatswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael L.","family":"Batteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Gaumond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"O\u2019Brate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2023.02.007_bib1","first-page":"1","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jval.2023.02.007_bib2","first-page":"122","article-title":"Treatment of advanced non small cell lung cancer","volume":"3","author":"Bareschino","year":"2011","journal-title":"J\u00a0Thorac Dis"},{"issue":"1","key":"10.1016\/j.jval.2023.02.007_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung cancer: will expectations finally be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jval.2023.02.007_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/1758835921992976","article-title":"Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer","volume":"13","author":"Hong","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"10.1016\/j.jval.2023.02.007_bib6","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1634\/theoncologist.2020-0760","article-title":"New verse for a familiar song: small molecule inhibitors for MET exon 14 skipping non-small cell lung cancer","volume":"25","author":"Le","year":"2020","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.jval.2023.02.007_bib7","doi-asserted-by":"crossref","first-page":"S784","DOI":"10.1016\/S1556-0864(21)02001-3","article-title":"159P Clinical characteristics of patients with advanced NSCLC and MET exon 14 (METex14) skipping: a systematic literature review","volume":"16","author":"Mazieres","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jval.2023.02.007_bib8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2021.06.015","article-title":"Real-world insights into patients with advanced NSCLC and MET alterations","volume":"159","author":"Bittoni","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jval.2023.02.007_bib9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/PO.20.00098","article-title":"CNS metastases in patients with MET exon 14\u2013altered lung cancers and outcomes with crizotinib","volume":"4","author":"Offin","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"15","key":"10.1016\/j.jval.2023.02.007_bib10","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1200\/JCO.2020.38.15_suppl.9575","article-title":"Tepotinib in patients (pts) with NSCLC with MET exon 14 (MET ex14) skipping: health-related quality of life (HRQoL)","volume":"38","author":"Paik","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2023.02.007_bib11","author":"Scott"},{"issue":"10","key":"10.1016\/j.jval.2023.02.007_bib12","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","volume":"29","author":"Sabari","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jval.2023.02.007_bib13","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jval.2023.02.007_bib14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring met mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.jval.2023.02.007_bib15","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/1078-0432.CCR-19-2860","article-title":"First-in-man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors","volume":"26","author":"Falchook","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jval.2023.02.007_bib16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40265-020-01317-9","article-title":"Tepotinib: First approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"suppl 4","key":"10.1016\/j.jval.2023.02.007_bib17","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jval.2023.02.007_bib19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jval.2023.02.007_bib20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","article-title":"Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice","volume":"28","author":"Le","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jval.2023.02.007_bib21","doi-asserted-by":"crossref","first-page":"S984","DOI":"10.1016\/j.annonc.2021.08.1857","article-title":"1254P Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC","volume":"32","author":"Garassino","year":"2021","journal-title":"Ann Oncol"},{"issue":"suppl 6","key":"10.1016\/j.jval.2023.02.007_bib22","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1016\/j.annonc.2022.05.043","article-title":"Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14) NSCLC (VISION)","volume":"33","author":"Morise","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jval.2023.02.007_bib23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40258-020-00620-6","article-title":"What is the impact of the analysis method used for health state utility values on QALYs in oncology? A simulation study comparing progression-based and time-to-death approaches","volume":"19","author":"Hatswell","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"10.1016\/j.jval.2023.02.007_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jval.2010.10.015","article-title":"Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals","volume":"14","author":"Tosh","year":"2011","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2023.02.007_bib25","doi-asserted-by":"crossref","first-page":"S1085","DOI":"10.1016\/j.jtho.2021.08.471","article-title":"P45.03 Tepotinib in patients with MET exon 14 skipping NSCLC as identified by liquid or tissue biopsy","volume":"16","author":"Felip","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.jval.2023.02.007_bib26","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.jval.2023.02.007_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.jval.2023.02.007_bib28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","article-title":"United States valuation of EQ-5D-5L health states using an international protocol","volume":"22","author":"Pickard","year":"2019","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2023.02.007_bib29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MLR.0000000000000447","article-title":"A\u00a0time trade-off-derived value set of the EQ-5D-5L for Canada","volume":"54","author":"Xie","year":"2016","journal-title":"Med Care"},{"issue":"12","key":"10.1016\/j.jval.2023.02.007_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209344","article-title":"Valuation of the EQ-5D-5L in Taiwan","volume":"13","author":"Lin","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jval.2023.02.007_bib33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"Van Hout","year":"2012","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2023.02.007_bib34","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"issue":"4","key":"10.1016\/j.jval.2023.02.007_bib35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/0272989X211003569","article-title":"United States utility algorithm for the EORTC QLU-C10D, a multiattribute utility instrument based on a cancer-specific quality-of-life instrument","volume":"41","author":"Revicki","year":"2021","journal-title":"Med Decis Making"},{"issue":"12","key":"10.1016\/j.jval.2023.02.007_bib36","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/hec.3950","article-title":"U.K. utility weights for the EORTC QLU-C10D","volume":"28","author":"Norman","year":"2019","journal-title":"Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2023.02.007_bib37","article-title":"The EORTC QLU-C10D: the Canadian valuation study and algorithm to derive cancer-specific utilities from the EORTC QLQ-C30","volume":"4","author":"McTaggart-Cowan","year":"2019","journal-title":"MDM Policy Pract"},{"key":"10.1016\/j.jval.2023.02.007_bib40","doi-asserted-by":"crossref","first-page":"S985","DOI":"10.1016\/j.annonc.2021.08.1858","article-title":"1255P Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)","volume":"32","author":"Reinmuth","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jval.2023.02.007_bib41","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/JTO.0b013e318299243b","article-title":"Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting","volume":"8","author":"Chouaid","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"issue":"7","key":"10.1016\/j.jval.2023.02.007_bib42","doi-asserted-by":"crossref","first-page":"A419","DOI":"10.1016\/j.jval.2013.08.550","article-title":"Health state utility values in advanced non-small cell lung cancer patients","volume":"16","author":"Chevalier","year":"2013","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.jval.2023.02.007_bib43","first-page":"1191","article-title":"Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US","volume":"21","author":"Insinga","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"7","key":"10.1016\/j.jval.2023.02.007_bib44","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1080\/03007995.2019.1571297","article-title":"Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US","volume":"35","author":"Insinga","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2023.02.007_bib45","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jval.2018.09.427","article-title":"Health state utilities in metastatic NSCLC: a study of multiple immuno-oncology trials","volume":"21","author":"Huang","year":"2018","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2023.02.007_bib46","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40273-017-0527-z","article-title":"Cost effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States","volume":"35","author":"Huang","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2023.02.007_bib47","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.jval.2018.04.300","article-title":"Systematic literature review (SLR) of health state utility values (HSUV) in epidermal growth factor receptor mutant (Egfr-mutant) non-small cell lung cancer (NSCLC) patients previously treated with targeted therapies","volume":"21","author":"Shor","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2023.02.007_bib48","doi-asserted-by":"crossref","first-page":"vi357","DOI":"10.1093\/annonc\/mdw377.21","article-title":"Health state utility measured by EQ-5D-5L for EGFRm T790M NSCLC patients treated with osimertinib","volume":"27","author":"Bodnar","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jval.2023.02.007_bib49","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/JTO.0000000000000318","article-title":"Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer","volume":"9","author":"Blackhall","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jval.2023.02.007_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12955-017-0748-z","article-title":"A\u00a0systematic literature review of health state utility values in head and neck cancer","volume":"15","author":"Meregaglia","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"18","key":"10.1016\/j.jval.2023.02.007_bib51","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1002\/cam4.2603","article-title":"Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer","volume":"8","author":"Jiang","year":"2019","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jval.2023.02.007_bib52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12955-014-0140-1","article-title":"Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death","volume":"12","author":"Hatswell","year":"2014","journal-title":"Health Qual Life Outcomes"},{"issue":"suppl 7","key":"10.1016\/j.jval.2023.02.007_bib53","doi-asserted-by":"crossref","first-page":"S1002","DOI":"10.1016\/j.annonc.2022.07.1112","article-title":"985P Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC","volume":"33","author":"Smit","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jval.2023.02.007_bib54","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0643","article-title":"Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer","volume":"3","author":"Marschner","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jval.2023.02.007_bib55","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2017.09.011","article-title":"Patient-reported outcome measures (PROMs) in the management of lung cancer: a systematic review","volume":"113","author":"Bouazza","year":"2017","journal-title":"Lung Cancer"},{"issue":"13","key":"10.1016\/j.jval.2023.02.007_bib56","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1200\/JCO.2010.33.4631","article-title":"Relationship between deficits in overall quality of life and non-small-cell lung cancer survival","volume":"30","author":"Sloan","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.jval.2023.02.007_bib57","doi-asserted-by":"crossref","first-page":"A744","DOI":"10.1016\/j.jval.2016.09.2276","article-title":"Measurement of utilities by time to death related to advanced non-small cell lung cancer in South Korea","volume":"19","author":"Chang","year":"2016","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2023.02.007_bib58","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-018-0058-3","article-title":"Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection","volume":"15","author":"Abbosh","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.jval.2023.02.007_bib59","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jval.2023.02.007_bib60","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/neuonc\/now197","article-title":"Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.jval.2023.02.007_bib61","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S1470-2045(17)30693-9","article-title":"Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain metastases working group","volume":"19","author":"Camidge","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523000566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523000566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:32:23Z","timestamp":1761096743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301523000566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1098301523000566"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2023.02.007","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2023.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}